Opthea terminates Wet AMD trials due to failure to meet primary endpoint

From GlobeNewswire: 2025-03-31 00:01:00

Opthea’s Phase 3 trial for wet AMD, ShORe, did not meet its primary endpoint of mean change in BCVA from baseline to week 52. The company decided to terminate both COAST and ShORe trials following the negative results. Sozinibercept combination therapy did not show significant improvements compared to standard of care. Opthea estimates having unaudited cash and cash equivalents of US$100M at the end of March 2025. Discussions with Development Funding Agreement investors are ongoing as Opthea faces uncertainty about its ability to continue as a going concern. Trading in Opthea’s listed securities will be suspended. Opthea faces various risks and uncertainties beyond its control, impacting future events and financial performance. Factors like capital requirements, regulatory risks, and labor costs may affect results. Actual outcomes may differ from projections due to changing circumstances. The company disclaims any obligation to update forward-looking statements unless required by law. For investor inquiries, contact PJ Kelleher at [email protected] or 617-430-7579. Join the email list for program updates at [email protected] or visit www.opthea.com. Refer to Opthea’s financial statements for additional information.



Read more at GlobeNewswire: Opthea Announces Decision to Discontinue Wet AMD Trials